S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
BCRX · BioCryst Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
BioCryst Pharmaceuticals Inc (BCRX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$7.73
-0.20
(-2.58%)
● At close: October 21 at 4:00:00 PM EDT
$7.72
-0.03
(-0.39%)
Overnight:
9:32:00 PM EDT
DAY'S RANGE
$7.73
$7.73
$8.04
52-WEEK RANGE
$7.73
$6.23
$11.22
What's happening
- BCRX is down 2.58% today, trading at $7.73. — Live quote
- Volume today (543,999) is well below its 3-month average of 4,783,430. (Finnhub fundamentals)
- Reports earnings on 2026-11-04 (before market open), 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.30 actual vs. $0.12 estimated (+148.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 9
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BCRX
+1.79%
vs S&P 500
-10.98%
1-YEAR RETURN
BCRX
+14.57%
vs S&P 500
+0.01%
6-MONTH RETURN
BCRX
-16.60%
3-MONTH RETURN
BCRX
-15.71%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.30
Est. $0.12
BEAT +148.1%
2026-04-26 (Q1 2026)
$-0.09
Est. $0.05
MISS -281.8%
2026-01-26 (Q4 2025)
$0.01
Est. $0.04
MISS -74.1%
2025-10-26 (Q3 2025)
$0.06
Est. $0.04
BEAT +67.1%
Valuation Measures & Ratios
Enterprise Value4$2.70B
Forward P/E5—
PEG Ratio6-0.01
Price / Sales (TTM1)2.16
Price / Book718.05
EV4 / Revenue2.87
EV4 / EBITDA8.30
Profit Margin-40.90%
Operating Margin-34.69%
Return on Equity (ROE8)-328.82%
Return on Assets (ROA9)-77.58%
Avg Volume (3M)4,783,430
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.61B | $2.31B | $1.63B | $2.28B | — |
| P/E | -4.17 | -3.28 | 409.13 | -105.52 | — |
| Price/Book | -5.75 | -4.16 | -4.20 | -5.40 | — |
| EV/EBITDA | — | — | 19.42 | — | — |
| ROE | 137.67% | 127.08% | -1.03% | 5.12% | — |
| ROA | -112.11% | -151.34% | 0.89% | -4.72% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short27,494,721
Change from Prior Settlement-21.15%
% of Float—
Days to Cover (Short Ratio)4.62
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 33.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +14.6%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -40.9%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BCRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | $98.5M | -$701.6M | $29.6M | $29.8M | $21.2M | $7.7M | $8.8M | -$14.5M |
| Net income | $78.4M | -$721.8M | $12.9M | $5.1M | $32.0K | -$14.0M | -$12.7M | -$35.4M |
| EPS (diluted) | $0.30 | $-2.98 | $0.06 | $0.02 | $0.00 | $-0.07 | $-0.06 | $-0.17 |
| EPS (basic) | $0.31 | $-2.98 | $0.06 | $0.02 | $0.00 | $-0.07 | $-0.06 | $-0.17 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $557.9M | $465.1M | $514.2M | $446.4M | $457.2M | $480.0M | $490.4M | $491.3M |
| Total liabilities | $1.01B | $1.02B | $633.3M | $834.3M | $878.8M | $932.0M | $966.4M | $959.8M |
| Stockholders' equity | -$454.3M | -$553.8M | -$119.2M | -$387.9M | -$421.6M | -$451.9M | -$475.9M | -$468.6M |
| Total current assets | $484.7M | $373.6M | $404.3M | $355.7M | $398.5M | $410.0M | $422.0M | $427.1M |
| Total current liabilities | $208.8M | $195.4M | $196.1M | $190.2M | $177.2M | $139.9M | $160.4M | $153.6M |
| Cash & equivalents | $155.0M | $171.6M | $89.7M | $84.1M | $88.0M | $105.2M | $104.7M | $96.8M |
| Marketable securities (current) | $197.6M | $66.8M | $185.0M | $128.8M | $172.0M | $189.9M | $216.1M | — |
| Accounts receivable | $110.8M | $109.3M | $106.8M | $91.3M | $91.2M | $93.4M | $79.1M | $72.5M |
| Inventory | $6.1M | $6.0M | $5.4M | $5.2M | $5.0M | $6.9M | $8.1M | $7.6M |
| Marketable securities (non-current) | $0 | $20.6M | $61.2M | $39.7M | $10.1M | $20.5M | $20.3M | $19.4M |
| Property, plant & equipment | $9.1M | $9.4M | $8.8M | $8.4M | $8.5M | $7.6M | $7.8M | $7.4M |
| Other non-current assets | $19.6M | $19.7M | $5.7M | $4.4M | $3.6M | $4.8M | $5.2M | $15.6M |
| Accounts payable | $11.5M | $11.0M | $15.8M | $5.6M | $8.6M | $10.0M | $11.6M | $13.5M |
| Accrued liabilities | $121.9M | $119.4M | $126.4M | $118.8M | $107.1M | $92.6M | $113.3M | $104.2M |
| Deferred revenue (current) | $12.3M | $5.4M | $0 | — | — | — | — | — |
| Long-term debt | $395.4M | $395.2M | $0 | $194.4M | $242.8M | $315.4M | $314.9M | $314.3M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $2.6M | $2.5M | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M |
| Retained earnings | -$2.15B | -$2.23B | -$1.51B | -$1.75B | -$1.76B | -$1.77B | -$1.77B | -$1.74B |
| Accumulated other comprehensive income (loss) | -$528.0K | -$368.0K | $38.0K | $1.1M | $1.6M | $1.1M | $921.0K | $2.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $104.3M | -$61.8M | $292.0M | $41.6M | $41.3M | -$27.5M | -$5.2M | $8.2M |
| Investing cash flow | -$110.1M | -$268.6M | -$83.5M | $13.6M | $29.1M | $27.1M | $17.8M | $8.5M |
| Financing cash flow | -$11.2M | $412.6M | -$218.0M | -$58.8M | -$73.7M | $529.0K | -$4.0M | $1.3M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K |
| Share-based compensation | $14.7M | $16.0M | $23.8M | $18.6M | $21.3M | $21.4M | $21.3M | $17.2M |
| Deferred income taxes | — | — | -$1.2M | — | — | — | -$354.0K | — |
| Change in inventory | $4.3M | $4.8M | $515.0K | $1.7M | -$1.4M | $870.0K | $2.2M | $1.5M |
| Change in accounts payable | $5.1M | -$60.4M | $35.4M | $24.6M | $30.5M | -$32.6M | $20.4M | $18.4M |
| Purchases of investments | $135.6M | $0 | $125.5M | $58.6M | $29.3M | $48.8M | $39.5M | $26.9M |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | $0 | $400.0M | $0 | — | $0 | $0 | $0 | $0 |
| Debt repaid | $0 | — | $184.2M | $46.3M | $69.5M | — | $0 | $0 |
| Tax withholding on stock comp | $3.7M | $1.2M | $6.0M | $628.0K | $866.0K | $1.4M | $3.1M | $261.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M | -$177.7M |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M | -$184.1M |
| EPS (diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| EPS (basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M |
| Total liabilities | $633.3M | $966.4M | $972.5M | — | — |
| Stockholders' equity | -$119.2M | -$475.9M | -$455.5M | -$294.6M | -$107.0M |
| Total current assets | $404.3M | $422.0M | $496.0M | $516.5M | $566.1M |
| Total current liabilities | $196.1M | $160.4M | $150.0M | $105.5M | $103.7M |
| Cash & equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M |
| Marketable securities (current) | $185.0M | $216.1M | — | — | — |
| Accounts receivable | $106.8M | $79.1M | $57.0M | $50.6M | $29.4M |
| Inventory | $5.4M | $8.1M | $28.7M | $27.5M | $15.8M |
| Marketable securities (non-current) | $61.2M | $20.3M | $0 | $18.1M | $6.8M |
| Property, plant & equipment | $8.8M | $7.8M | $7.9M | $8.6M | $8.7M |
| Other non-current assets | $5.7M | $5.2M | $80.0K | $6.8M | $6.5M |
| Accounts payable | $15.8M | $11.6M | $20.9M | $14.4M | $27.8M |
| Accrued liabilities | $126.4M | $113.3M | $102.9M | $87.6M | $72.7M |
| Long-term debt | $0 | $314.9M | $303.2M | $231.6M | $136.1M |
| Common stock & paid-in capital | $2.1M | $2.1M | $2.1M | $1.9M | $1.8M |
| Retained earnings | -$1.51B | -$1.77B | -$1.68B | -$1.45B | -$1.21B |
| Accumulated other comprehensive income (loss) | $38.0K | $921.0K | $1.3M | $26.0K | $177.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M |
| Investing cash flow | -$13.7M | $52.6M | -$131.5M | -$128.2M | $15.8M |
| Financing cash flow | -$349.9M | -$5.8M | $32.5M | $88.0M | $359.7M |
| Capital expenditures | — | — | — | — | — |
| Depreciation & amortization | $1.4M | $1.2M | $1.7M | $1.4M | $777.0K |
| Share-based compensation | $85.1M | $65.4M | $55.6M | $44.7M | $34.6M |
| Deferred income taxes | -$1.2M | -$354.0K | -$682.0K | $11.0K | -$159.0K |
| Change in inventory | $1.6M | $4.2M | $1.4M | $12.4M | $8.8M |
| Change in accounts payable | $57.8M | $14.8M | $12.5M | -$22.4M | $39.4M |
| Purchases of investments | $262.2M | $266.8M | $514.4M | $244.3M | $10.0M |
| Share repurchases | — | — | — | — | — |
| Debt issued | $0 | $0 | $300.0M | $73.1M | $0 |
| Debt repaid | $300.0M | $0 | $240.5M | — | — |
| Tax withholding on stock comp | $8.8M | $7.5M | $2.2M | $0 | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BCRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-27 to 2026-08-31
Recent transactions
- Insiders have net sold 73,680 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Stonehouse Jon P (Director) — Grant / award of 644 shares on 2026-08-31.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)73,680 sh(2 txns)
Net Shares-73,680
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Stonehouse Jon P | Director | Grant / award | 2026-08-31 | 644 |
| Milne Jill C. | Director | Grant / award | 2026-08-31 | 1,288 |
| MILANO VINCENT | Director | Grant / award | 2026-08-31 | 1,159 |
| McKee Amy E | Director | Grant / award | 2026-08-31 | 644 |
| Frank Steven | Director | Grant / award | 2026-08-31 | 1,288 |
| Galson Steven K | Director | Grant / award | 2026-06-11 | 15,294 |
| LEVIN ALAN G | Director | Grant / award | 2026-06-11 | 15,294 |
| SANDERS MACHELLE | Director | Grant / award | 2026-06-11 | 15,294 |
| HEGGIE THERESA | Director | Grant / award | 2026-06-11 | 15,294 |
| Barnes Alane P | Chief Legal Officer | Option exercise | 2026-05-13 | 62,500 |
| Menon Sandeep | Chief R&D Officer | Grant / award | 2026-04-06 | 205,150 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Stonehouse Jon P | Director | Grant / award | 644 | $9.70 |
| 2026-08-31 | Milne Jill C. | Director | Grant / award | 1,288 | $9.70 |
| 2026-08-31 | MILANO VINCENT | Director | Grant / award | 1,159 | $9.70 |
| 2026-08-31 | McKee Amy E | Director | Grant / award | 644 | $9.70 |
| 2026-08-31 | Frank Steven | Director | Grant / award | 1,288 | $9.70 |
| 2026-06-11 | Milne Jill C. | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | Galson Steven K | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | LEVIN ALAN G | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | Frank Steven | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | SANDERS MACHELLE | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | MILANO VINCENT | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | Stonehouse Jon P | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | McKee Amy E | Director | Grant / award | 15,294 | $0.00 |
| 2026-06-11 | HEGGIE THERESA | Director | Grant / award | 15,294 | $0.00 |
| 2026-05-29 | Milne Jill C. | Director | Grant / award | 1,262 | $8.91 |
| 2026-05-29 | Stonehouse Jon P | Director | Grant / award | 631 | $8.91 |
| 2026-05-29 | McKee Amy E | Director | Grant / award | 631 | $8.91 |
| 2026-05-29 | MILANO VINCENT | Director | Grant / award | 1,122 | $8.91 |
| 2026-05-29 | Frank Steven | Director | Grant / award | 1,262 | $8.91 |
| 2026-05-18 | McKee Amy E | Director | Open market sale | 11,180 | $8.97 |
| 2026-05-13 | Barnes Alane P | Chief Legal Officer | Option exercise | 62,500 | $5.04 |
| 2026-05-13 | Barnes Alane P | Chief Legal Officer | Open market sale | 62,500 | $9.54 |
| 2026-04-06 | Menon Sandeep | Chief R&D Officer | Grant / award | 205,150 | $0.00 |
| 2026-03-20 | HEGGIE THERESA | Director | Option exercise | 49,933 | $6.30 |
| 2026-03-20 | HEGGIE THERESA | Director | Open market sale | 49,933 | $10.11 |
| 2026-03-16 | Barnes Alane P | Chief Legal Officer | Option exercise | 150,000 | $5.51 |
| 2026-03-16 | Barnes Alane P | Chief Legal Officer | Open market sale | 150,000 | $9.15 |
| 2026-02-27 | Milne Jill C. | Director | Grant / award | 528 | $8.75 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:26 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about BCRX (BioCryst Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
BioCryst to Report Third Quarter 2026 Financial Results on November 4
Yahoo Finance · 2026-10-21 -
BioCryst wins FDA nod for Orladeyo oral pellets
Seeking Alpha · 2026-10-21 -
BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ)
Seeking Alpha · 2026-10-21 -
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
Yahoo Finance · 2026-10-21 -
AMN,HLF,PGY,BSBK,FXNC,IMRX,CRMT,MRBK,ORN,TISI,FRST,GRNT,VSTS,GEF-B,RVSB,SHEN,DCGO,SABR,TMCI,BCRX,NBBK,USCB | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
BioCryst Pharmaceuticals stock gains 2.32 percent at EUR 7.06
AD HOC NEWS · 2026-10-20 -
AMN,HLF,BSBK,FXNC,IMRX,CRMT,MRBK,ORN,TISI,FRST,GRNT,VSTS,GEF-B,RVSB,DCGO,TMCI,SABR,SHEN,BCRX,NBBK,USCB | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-20 -
AMN,HLF,BSBK,FXNC,IMRX,CRMT,MRBK,ORN,TISI,FRST,GRNT,VSTS,RVSB,GEF-B,DCGO,SHEN,TMCI,BCRX,SABR,NBBK,USCB | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-20
No headlines in this category right now — try “All”.